10 research outputs found
Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development
DNA methyltransferase 3A (DNMT3A) is frequently mutated in hematological cancers; however, the underlying oncogenic mechanism remains elusive. Here, we report that DNMT3A mutational hotspot at Arg882 (DNMT3AR882H) cooperates with NRAS mutation to transform hematopoietic stem/progenitor cells and induce acute leukemia development. Mechanistically, DNMT3AR882H directly binds to and potentiates transactivation of stemness genes critical for leukemogenicity including Meis1, Mn1 and Hoxa gene cluster. DNMT3AR882H induces focal epigenetic alterations, including CpG hypomethylation and concurrent gain of active histone modifications, at cis-regulatory elements such as enhancers to facilitate gene transcription. CRISPR/Cas9-mediated ablation of a putative Meis1 enhancer carrying DNMT3AR882H-induced DNA hypomethylation impairs Meis1 expression. Importantly, DNMT3AR882H-induced gene expression programs can be repressed through Dot1l inhibition, providing an attractive therapeutic strategy for DNMT3A-mutated leukemias
Recommended from our members
Reactivation of Myc transcription in the mouse heart unlocks its proliferative capacity
Abstract: It is unclear why some tissues are refractory to the mitogenic effects of the oncogene Myc. Here we show that Myc activation induces rapid transcriptional responses followed by proliferation in some, but not all, organs. Despite such disparities in proliferative response, Myc is bound to DNA at open elements in responsive (liver) and non-responsive (heart) tissues, but fails to induce a robust transcriptional and proliferative response in the heart. Using heart as an exemplar of a non-responsive tissue, we show that Myc-driven transcription is re-engaged in mature cardiomyocytes by elevating levels of the positive transcription elongation factor (P-TEFb), instating a large proliferative response. Hence, P-TEFb activity is a key limiting determinant of whether the heart is permissive for Myc transcriptional activation. These data provide a greater understanding of how Myc transcriptional activity is determined and indicate modification of P-TEFb levels could be utilised to drive regeneration of adult cardiomyocytes for the treatment of heart myopathies
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
EZH2 or EZH1 is the catalytic subunit of the polycomb repressive complex 2 that catalyzes methylation of histone H3 lysine 27 (H3K27). The trimethylation of H3K27 (H3K27me3) is a transcriptionally repressive post-translational modification. Overexpression of EZH2 and hypertrimethylation of H3K27 have been implicated in a number of cancers. Several selective inhibitors of EZH2 have been reported recently. Herein we disclose UNC1999, the first orally bioavailable inhibitor that has high in vitro potency for wild-type and mutant EZH2 as well as EZH1, a closely related H3K27 methyltransferase that shares 96% sequence identity with EZH2 in their respective catalytic domains. UNC1999 was highly selective for EZH2 and EZH1 over a broad range of epigenetic and non-epigenetic targets, competitive with the cofactor SAM, and non-competitive with the peptide substrate. This inhibitor potently reduced H3K27me3 levels in cells and selectively killed diffused large B cell lymphoma cell lines harboring the EZH2Y641N mutant. Importantly, UNC1999 was orally bioavailable in mice, making this inhibitor a valuable tool for investigating the role of EZH2 and EZH1 in chronic animal studies. We also designed and synthesized UNC2400, a close analog of UNC1999 with >1,000-fold lower potency than UNC1999 as a negative control for cell-based studies. Finally, we created a biotin-tagged UNC1999 (UNC2399) which enriched EZH2 in pull-down studies, and a UNC1999 – dye conjugate (UNC2239) for co-localization studies with EZH2 in live cells. Taken together, these compounds represent a set of useful tools for the biomedical community to investigate the role of EZH2 and EZH1 in health and disease
Constructivist social work and personal construct theory: the case of psychological trauma
The complex and changing relationship between theory and practice in social work has received increasing attention in recent years. Parton (2000) has advocated a constructionist approach that underlines the similarity between the roles of the researcher and the practitioner. Personal construct theory (Kelly, 1955) is one member of the constructionist family that has particular implications for social work practice. It evolved as a pragmatic approach to psychotherapy, advocating a research supervisor/student model of the practitioner/client relationship. In this article, we elaborate its application to social work practice, drawing on contemporary work in the fields of trauma and loss to illustrate its value
Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development
DNA methyltransferase 3A (DNMT3A) is frequently mutated in hematological cancers; however, the underlying oncogenic mechanism remains elusive. Here, we report that DNMT3A mutational hotspot at Arg882 (DNMT3A(R882H)) cooperates with NRAS mutation to transform hematopoietic stem/progenitor cells and induce acute leukemia development. Mechanistically, DNMT3A(R882H) directly binds to and potentiates transactivation of stemness genes critical for leukemogenicity including Meis1, Mn1 and Hoxa gene cluster. DNMT3A(R882H) induces focal epigenetic alterations, including CpG hypomethylation and concurrent gain of active histone modifications, at cis-regulatory elements such as enhancers to facilitate gene transcription. CRISPR/Cas9-mediated ablation of a putative Meis1 enhancer carrying DNMT3A(R882H)-induced DNA hypomethylation impairs Meis1 expression. Importantly, DNMT3A(R882H)-induced gene expression programs can be repressed through Dot1l inhibition, providing an attractive therapeutic strategy for DNMT3A-mutated leukemias
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
EZH2 or EZH1 is the catalytic subunit
of the polycomb repressive
complex 2 that catalyzes methylation of histone H3 lysine 27 (H3K27).
The trimethylation of H3K27 (H3K27me3) is a transcriptionally repressive
post-translational modification. Overexpression of EZH2 and hypertrimethylation
of H3K27 have been implicated in a number of cancers. Several selective
inhibitors of EZH2 have been reported recently. Herein we disclose
UNC1999, the first orally bioavailable inhibitor that has high <i>in vitro</i> potency for wild-type and mutant EZH2 as well as
EZH1, a closely related H3K27 methyltransferase that shares 96% sequence
identity with EZH2 in their respective catalytic domains. UNC1999
was highly selective for EZH2 and EZH1 over a broad range of epigenetic
and non-epigenetic targets, competitive with the cofactor SAM and
non-competitive with the peptide substrate. This inhibitor potently
reduced H3K27me3 levels in cells and selectively killed diffused large
B cell lymphoma cell lines harboring the EZH2<sup>Y641N</sup> mutant.
Importantly, UNC1999 was orally bioavailable in mice, making this
inhibitor a valuable tool for investigating the role of EZH2 and EZH1
in chronic animal studies. We also designed and synthesized UNC2400,
a close analogue of UNC1999 with potency >1,000-fold lower than
that
of UNC1999 as a negative control for cell-based studies. Finally,
we created a biotin-tagged UNC1999 (UNC2399), which enriched EZH2
in pull-down studies, and a UNC1999–dye conjugate (UNC2239)
for co-localization studies with EZH2 in live cells. Taken together,
these compounds represent a set of useful tools for the biomedical
community to investigate the role of EZH2 and EZH1 in health and disease